Cargando…

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients

BACKGROUND: Circulating tumor DNA (ctDNA) levels correlate well with tumor bulk. In this paper we aim to estimate the prognostic value of the dynamic quantification of ctDNA levels. MATERIALS AND METHODS: A total of 251 serial plasma samples from 41 non-small-cell lung cancer patients who carried an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Provencio, Mariano, Torrente, María, Calvo, Virginia, Pérez-Callejo, David, Gutiérrez, Lourdes, Franco, Fernando, Pérez-Barrios, Clara, Barquín, Miguel, Royuela, Ana, García-García, Francisco, Bueno, Coralia, Garcia-Grande, Aranzazu, Camps, Carlos, Massuti, Bartomeu, Sotomayor, Eduardo, Romero, Atocha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787483/ https://www.ncbi.nlm.nih.gov/pubmed/29416630 http://dx.doi.org/10.18632/oncotarget.22470

Ejemplares similares

Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment
por: Provencio, Mariano, et al.
Publicado: (2017)

ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
por: Romero, Atocha, et al.
Publicado: (2020)

Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients
por: Provencio, Mariano, et al.
Publicado: (2017)

PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy
por: Cruz-Bermúdez, Alberto, et al.
Publicado: (2017)

Long-term follow up of Hodgkin lymphoma
por: Perez-Callejo, David, et al.
Publicado: (2018)

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
por: Sánchez-Herrero, Estela, et al.
Publicado: (2022)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
por: Sánchez‐Herrero, Estela, et al.
Publicado: (2021)

Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC
por: Garitaonaindia, Yago, et al.
Publicado: (2023)

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
por: Provencio, Mariano, et al.
Publicado: (2022)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Utilidad clínica de la biopsia líquida para el diagnóstico y seguimiento de los pacientes con CPNM y EML4-ALK
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Comprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial
por: Romero, Atocha, et al.
Publicado: (2020)

Patterns and outcome of unplanned care in lung cancer patients: an observational study in a medical oncology department
por: Sánchez, Juan C., et al.
Publicado: (2023)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
por: Sierra-Rodero, Belén, et al.
Publicado: (2021)

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
por: Gutiérrez, Lourdes, et al.
Publicado: (2021)

Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study
por: Provencio, Mariano, et al.
Publicado: (2023)

Functional Signatures in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Sex-Based Differences in Transcriptomic Studies
por: Pérez-Díez, Irene, et al.
Publicado: (2021)

To burn-out or not to burn-out: a cross-sectional study in healthcare professionals in Spain during COVID-19 pandemic
por: Torrente, Maria, et al.
Publicado: (2021)

¿Puede la calidad del cuidado del paciente oncológico ser mejorada?: resultados de la puesta en marcha de una línea de atención telefónica en la enfermería oncológica
por: Jara González, Eduardo, et al.
Publicado: (2014)

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
por: Torrente, María, et al.
Publicado: (2022)

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2021)

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
por: Laza‐Briviesca, Raquel, et al.
Publicado: (2021)

CB(2) cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3β signaling pathway
por: Martínez-Martínez, Esther, et al.
Publicado: (2016)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022)

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
por: Provencio, Mariano, et al.
Publicado: (2022)

Cost-effectiveness of diagnostic tests during follow-up in lung cancer patients: an evidence-based study
por: Rodríguez-Cano, Fernando, et al.
Publicado: (2023)

Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review
por: Calvo, Virginia, et al.
Publicado: (2021)

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
por: Provencio, Mariano, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

Cancer as an infective disease: the role of EVs in tumorigenesis
por: Robado de Lope, Lucia, et al.
Publicado: (2022)

Cancer and SARS-CoV-2 Infection: A Third-Level Hospital Experience
por: Calvo, Virginia, et al.
Publicado: (2021)

ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC)
por: Masfarré, Laura, et al.
Publicado: (2021)

Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review
por: Ortega-Franco, Ana, et al.
Publicado: (2020)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma
por: Blanco, Mariola, et al.
Publicado: (2022)

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
por: Jantus-Lewintre, Eloisa, et al.
Publicado: (2021)

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
por: Franco, Fernando, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5n3e1u971nl9is86kt5b0q9c9s